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Abstract 
Each of the two steps involved in bile acid conjugation was tested in vitro for its sensitivity to inhibition by cyclosporin A (CsA). Bile 
acid-CoA: glycine/taurine N-acyltransferase, the enzyme which catalyzes the second step, was tested and found to be insensitive to 
inhibition by 20/xM CsA. Bile acid:CoA ligase, the enzyme which catalyzes the first step, was found to be inhibited by 25% at 10/xM 
CsA in the standard assay. The inhibition was competitive vs. bile acid and noncompetitive s. ATP, and uncompetitive vs. CoA. CsA 
was also found to interfere with the divalent cation requirement of the enzyme at low concentrations of Mg 2+ the maximum inhibition 
was 70%. The maximum inhibition obtainable at physiologic Mg 2÷ concentration was 40%. The extent of inhibition was presumably 
limited by the insolubility of CsA. At concentrations of CsA reached in vivo during drug therapy, CsA can be expected to significantly 
inhibit bile acid conjugation. 
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I. Introduction 
Cyclosporin A (CsA) is a fungus-derived immuno- 
suppressive agent which is pivotal for successful organ 
transplantation and its' finding increased usage in the 
treatment of some autoimmune diseases and dermatologi- 
cal disorders [1,2]. The effectiveness of CsA improves 
with dose, but unfortunately CsA treatment can be associ- 
ated with a number of side effects. One of these is hepatic 
dysfunction. CsA causes cholestasis in many patients [3], 
and has been found to consistently cause an accumulation 
of bilirubin and bile acids in blood [4]. Studies in rats in 
vivo and in human and rat hepatocytes in vitro have 
related this hepatic dysfunction to a CsA-induced ecrease 
in the hepatic uptake of bile acids [5-8]. The focus of the 
research in our laboratory has been on the conjugation of 
bile acids with glycine or taurine, and we have previously 
found that the hepatic uptake and biliary excretion of bile 
acids is dependent upon efficient conjugation [9]. It thus 
seemed reasonable to hypothesize that CsA decreases the 
hepatic uptake of bile acids by inhibiting bile acid conjuga- 
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tion. To test this hypothesis we studied the effect of CsA 
on bile acid conjugation. Bile acid conjugation occurs in 
two steps, there is an initial formation of bile acid-CoA 
catalyzed by bile acid:CoA ligase (E.C. 6.2.1.17) followed 
by reaction of this intermediate with either glycine or 
taurine, catalyzed by bile acid-CoA:glycine/taurine N-
acyltransferase (E.C. 2.3.1.65). In this work, each of these 
steps was examined in vitro for its sensitivity to inhibition 
by CsA. 
2. Materials and methods 
[2,4-3H]Cholic acid was obtained from NEN Research 
Products, Wilmington, DE. Cyclosporin A was kindly 
provided by Sandoz Pharmaceuticals, Basel, Switzerland. 
Cholyl-CoA was prepared as described previously [10]. 
Coenzyme A (CoA), adenosine triphosphate (ATP), 5,5'- 
dithiobis(2-nitrobenzoic) a id, ammonium sulfate, Hepes, 
Trizma Pre-set pH crystals, leupeptin, chymostatin, and 
pepstatin A were obtained from the Sigma Chemical, St. 
Louis, MO. 
Guinea pig liver microsomes were prepared by homoge- 
nizing freshly excised guinea pig liver in 4 vol. of cold 
0.25 M sucrose, 5 mM EDTA and 5 mM EGTA, contain- 
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ing 250 /zg/ l  each of the protease inhibitors leupeptin, 
chymostatin, and pepstatin A. Microsomes were isolated as 
described previously [11]. The final microsomal pellet was 
resuspended in cold 0.25 M sucrose to approx. 30 mg 
protein/ml and stored in aliquots at - 80 ° C. 
A partially purified preparation of bovine liver N-acyl- 
transferase was prepared from liver obtained fresh from a 
local slaughterhouse. The liver was homogenized in 0.13 
M KC1, 20 mM Hepes (pH 7.4), 1 mM EDTA, 1 mM 
EGTA, and 0.25 mg/1 of each of the protease inhibitors 
leupeptin, chymostatin, and pepstatin A at 5 ° C. The ho- 
mogenate was centrifuged for 20 min at I0 K rpm, and the 
supernatant centrifuged an additional 45 rain at 38 K rpm. 
The resulting supernatant was filtered through cheesecloth, 
and a 40 to 55% ammonium sulfate fraction isolated. The 
final pellet was dissolved in a minimal volume of 25 mM 
potassium phosphate (pH 8.0) and dialyzed against 50 vol. 
of this buffer and stored at - 80 ° C. 
The reaction of [3H]cholate with coenzyme A as cat- 
alyzed by guinea pig liver microsomes was determined 
radiochemically as described previously [12]. Assays were 
conducted at 30 ° C and the standard reaction contained 100 
mM Tris (pH 7.4), 1 mM MnC12, 10 /zM CoA, 7.0 /zM 
[3H]Cholate, 1 mM ATP, and 0 or 25 /xM CsA. The 
reaction of cholyl-CoA with glycine as catalyzed by bovine 
liver N-acyltransferase was determined spectrophotometri- 
caily using the 5,5'-dithiobis(2-nitrobenzoic) acidreaction 
[13]. The standard reaction contained 0.1 mM 5,5'-dithio- 
bis(2-nitrobenzoic) acid, 100 mM potassium phosphate 
(pH 8.0), 20 /~M choloyl-CoA, and 75 /zg of partially 
purified bovine liver N-acyitransferase protein in a 1 ml 
volume. The reaction was initiated by the addition of 
glycine and the absorbance monitored at 412 nm at 30 ° C. 
3. Results 
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Fig. 1. Double reciprocal plot of the cholic acid dependence of the rate of 
the ligase reaction in the presence or absence of cyclosporin A. Ligase 
activity was determined at variable concentrations of [3H]cholate, in 
either the presence (O), or absence (C)) of 25/~M cyclosporin A (CsA). 
inhibition. We first tested the inhibition as a function of 
the concentration of cholate (Fig. l). Inhibition by 25 /zM 
CsA was eliminated at extrapolated infinite concentration 
of cholate indicating that CsA is a competitive inhibitor of 
cholate binding. 
When the concentration of cholate was saturating, inhi- 
bition was still obtained if the concentration Mn 2+ or 
Mg 2+ was lowered (60% inhibition at 30/xM Mg 2+). The 
double reciprocal plots of 1 /v  vs. 1/Mg 2+ were non-lin- 
ear, but extrapolated to a common intercept suggesting a
competitive type inhibition. The ligase is known to have a 
complicated ivalent cation requirement [14], and thus the 
Mg2+-dependence of CsA inhibition was not readily ana- 
lyzable. When CsA was tested vs. CoA, the lines in the 
Bile acid conjugation is catalyzed by two enzymes 
working sequentially. A CoA adduct of the bile acid is first 
formed by a microsomal membrane-bound bile acid:CoA 
ligase and then a soluble fraction bile acid- 
CoA:glycine/taurine N-acyltransferase catalyzes the sub- 
sequent ransfer of the acyl group to the amino group of 
glycine or taurine. We have examined each of these two 
enzymes in vitro for their sensitivity to inhibition by CsA. 
A partially purified preparation of bovine liver N-acyl- 
transferase was tested for inhibition by 20 p~M CsA. The 
concentration of cholyl-CoA was varied from 2 to 20/xM 
and the concentration of glycine from 0.5 to 50 mM. There 
was no inhibition detectable at any concentration of these 
substrates. 
We next tested the bile acid:CoA ligase for sensitivity 
to CsA using the microsomal cell fraction as the source of 
the enzyme. Using a standard assay, the addition of 10 
/xM CsA to the reaction led to 25% inhibition of the 
ligase. We therefore proceeded to a kinetic analysis of the 
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Fig. 2. Double reciprocal plot of the CoA dependence of the rate of the 
ligase reaction in the presence or absence of cyclosporin A. Ligase 
activity was determined at variable concentrations of CoA in either the 
presence (O), or absence (C)) of 25 /xM cyclosporin A (CsA). 
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Fig. 3. Double reciprocal plot of the ATP dependence of the rate of the 
ligase reaction in the presence or absence of cyclosporin A. Ligase 
activity was determined atvariable concentrations of ATP in either the 
presence (0), or absence (O) of 25 /xM cyclosporin A (CsA). 
double reciprocal plot were parallel (Fig. 2). This suggests 
that CsA is an uncompetitive inhibitor vs. CoA. When 
CsA was tested for inhibition vs. ATP it gave a pattern of 
double reciprocal plots consistent with noncompetitive in- 
hibition (Fig. 3). 
Veloso et al. [15] have estimated that the physiologic 
concentration of Mg 2÷ is approx. 1 mM. Therefore, to 
measure the dependence of the inhibition on the concentra- 
tion of CsA, we employed 1 mM Mg 2+. We did this at 
several different non-saturating concentrations of cholate. 
A Dixon plot [16] of the data is shown in Fig. 4. The 
maximum inhibition obtainable at any concentration of 
cholate is approx. 40%. There is a high affinity inhibition 
from 0 to 10 /xM which accounts for approx. 30% inhibi- 
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Fig. 4. Dixon plot of the inhibition of the ligase by cyclosporin A. Ligase 
activity was determined in the presence of the indicated concentrations of 
cyclosporin A (CsA), at each of 3 different concentrations of [3H]cholate, 
0.8 /~M ('7), 2 /xM (O), and 10 p.M (O). 
tion. This inhibition has a K l of 22 /zM. However, 
beyond 10 /zM CsA the extent of inhibition increases 
little, probably because one is approaching the limits of 
CsA solubility (approx. 10 to 20 /zM). 
Also, the concentration dependence of CsA inhibition 
was measured as a function of the Mg 2÷ concentration but 
in the presence of saturating cholate (10 /zM). A Dixon 
plot of the data was similar to that shown in Fig. 2. There 
was a linear high affinity inhibition from 0 to 10/xM CSA 
which accounted for approx. 40% inhibition. This inhibi- 
tion had a K~ of 11 ~M. Beyond 10 /zM CsA the extent 
of inhibition increased little, again probably due to the 
limited solubility of CsA. 
4. Discussion 
Bile acid conjugation occurs in two steps involving the 
formation of an intermediate CoA adduct of the bile acid, 
followed by transfer of the acyl group to the amino group 
of glycine or taurine. CsA failed to inhibit the final step in 
conjugation, i.e., the N-acyltransferase catalyzed reaction. 
However, this is less consequential because the first step, 
the bile acid:CoA ligase-catalyzed synthesis of an acyl-CoA 
is inhibited by CsA, and this is the rate determining step in 
bile acid conjugation [17]. Thus, the extent of the inhibi- 
tion of the ligase by CsA should approximate the extent of 
the overall inhibition of bile acid conjugation. 
The data in Fig. 1 indicate that, at physiologic Mg 2+, 
CsA was a competitive inhibitor vs. cholate. This indicates 
that CsA inhibits by binding at the cholate binding site. 
The inhibition vs. CoA was uncompetitive. This is what 
one would expect since the ligase follows a ping-pong 
mechanism in which cholate and ATP bind first and then 
the product pyrophosphate is released prior to CoA bind- 
ing [18]. For an inhibitor binding at the cholate binding 
site, there is an irreversible step (product release) between 
the binding of CsA and the binding of CoA, and this 
generates an uncompetitive inhibition pattern vs. CoA. 
CsA was also a competitive inhibitor versus Mg 2+, with a 
K l of 11 /~M. However, at physiologic concentrations of 
Mg ~+ (approx. 1 raM, see Ref. [15]), the effect of this 
inhibition was nil. 
Study of the concentration dependence of the inhibition 
by CsA indicated that complete inhibition was not ob- 
tained within the limits of solubility of CsA. Indeed, it 
would appear that it is the limited solubility of CsA that 
limits the extent of inhibition and accounts for the non-lin- 
earity of the plots in Fig. 2. The limit of solubility is 
approx. 10 /~M in buffer, but higher concentrations were 
obtained in the presence of microsomes. The maximum 
inhibition achieved was 40%; and 30% inhibition was 
achievable by 10 /zM CsA. This is a very low concentra- 
tion and is in the range readily achieved during organ 
transplantation, particularly if an immediate post-operative 
period of intravenous infusion with CsA is employed. The 
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upper limit of therapeutic blood level is approx. 1 to 2 /zM 
[19] and hepatic levels are higher [20]. Further, CsA is 
primarily metabolized in the liver and eliminated in the 
bile [21]. Thus, in the case of transplantation f the liver 
where postoperatively the level of bile secretion is low [22] 
and the occurrence of biliary obstruction common [23], the 
cyclosporin level will be even higher in this period. As- 
suming that the ligase from human liver has the same 
sensitivity to CsA as the guinea pig enzyme, then it would 
be predicted that significant inhibition of bile acid conjuga- 
tion occurs in vivo during CsA therapy. Such inhibition 
would contribute to the decreased hepatic uptake of bile 
acids noted previously [5-8]. Since bilirubin uptake is also 
decreased by CsA [4], it is suggested that other factors may 
also contribute. 
In conclusion, CsA has been found to be an effective 
inhibitor of bile acid:CoA ligase activity in vitro due to 
binding at the bile acid binding site. The low inhibition 
constant suggests that cyclosporin levels common to drug 
therapy can be expected to lead to inhibition of bile acid 
conjugation i  vivo. 
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